LUTRONIC 410220 Mosaic 3D Surgical Laser Instruction Manual
- June 1, 2024
- LUTRONIC
Table of Contents
LUTRONIC 410220 Mosaic 3D Surgical Laser
Specifications
- Trade/Device Name: MOSAIC 3D (Surgical Laser)
- Regulation Number: 21 CFR 878.4810
- Regulation Name: Laser Surgical Instrument For Use In General And Plastic Surgery And In Dermatology
- Regulatory Class: Class II
- Product Code: ONG, GEX
Product Information
The MOSAIC 3D Laser System is designed for dermatological procedures that involve the coagulation of soft tissue and fractional skin resurfacing. It is a Class II laser surgical instrument used in general surgery, plastic surgery, and dermatology.
Product Usage Instructions
Indications for Use
The MOSAIC 3D Laser System is indicated for use in dermatological
procedures requiring the coagulation of soft tissue and fractional skin
resurfacing.
Type of Use
This device is for Prescription Use (Part 21 CFR 801 SubpartD).
Precautions
- Only use the device as directed by a qualified healthcare professional.
- Avoid direct contact with eyes and mucous membranes.
- Ensure proper calibration and maintenance of the device.
Usage Steps
- Prepare the treatment area by cleaning and sterilizing the skin.
- Select the appropriate settings on the laser system for the specific procedure.
- Administer the laser treatment following the recommended technique for coagulation or skin resurfacing.
- Monitor the patient for any adverse reactions during and after the procedure.
FAQ
-
Q: Can the MOSAIC 3D Laser System be used for all skin types?
A: The device can be used on various skin types, but it is recommended to consult with a healthcare professional to determine suitability for individual skin conditions. -
Q: How often should the device be calibrated?
A: The device should be calibrated according to the manufacturer’s recommendations, typically before each use or as specified in the maintenance guidelines.
January 2, 2024
- Lutronic Aesthetic
- ℅ Kevin O’connell
- VP Global Regulatory Affairs Lutronic Corporation
- Lutronic Center
- 219, Sowon-Ro
- Deogyang-Gu, Goyang-si 410220 Korea, South
- Re: K233550
- Trade/Device Name: MOSAIC 3D (Surgical Laser)
- Regulation Number: 21 CFR 878.4810
- Regulation Name: Laser Surgical Instrument For Use In General And Plastic Surgery And In
- Dermatology
- Regulatory Class: Class II
- Product Code: ONG, GEX
- Dated: November 3, 2023
- Received: November 3, 2023
Dear Kevin O’connell:
We have reviewed your section 510(k) premarket notification of intent to
market the device referenced above and have determined the device is
substantially equivalent (for the indications for use stated in the enclosure)
to legally marketed predicate devices marketed in interstate commerce prior to
May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the
Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of
a premarket approval application (PMA). You may, therefore, market the device,
subject to the general controls provisions of the Act. Although this letter
refers to your product as a device, please be aware that some cleared products
may instead be combination products. The 510(k) Premarket Notification
Database available at
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies
combination product submissions. The general controls provisions of the Act
include requirements for annual registration, listing of devices, good
manufacturing practice, labeling, and prohibitions against misbranding and
adulteration. Please note: CDRH does not evaluate information related to
contract liability warranties. We remind you, however, that device labeling
must be truthful and not misleading.
If your device is classified (see above) into either class II (Special
Controls) or class III (PMA), it may be subject to additional controls.
Existing major regulations affecting your device can be found in the Code of
Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish
further announcements concerning your device in the Federal Register.
K233550 – Kevin O’connell
-
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled “Deciding When to Submit a 510(k) for a Change to an Existing Device” (https://www.fda.gov/media/99812/download) and “Deciding When to Submit a 510(k) for a Software Change to an Existing Device” (https://www.fda.gov/media/99785/download).
-
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
-
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
-
Also, please note the regulation entitled, “Misbranding by reference to premarket notification” (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
-
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn
(https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive- regulatory-assistance/contact-us-division-industry-and-consumer-education- dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely, -
Jianting Wang -S
- Digitally signed by Jianting Wang -S
- Date: 2024.01.02 20:19:37 -05’00’
- for Tanisha Hithe
-
Assistant Director
- DHT4A: Division of General Surgery Devices
- OHT4: Office of Surgical & Infection Control Devices Office of Product Evaluation and Quality
- Center for Devices and Radiological Health
-
Enclosure
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: 07/31/2026
See PRA Statement below.
- 510(k) Number (if known) K233550
- Device Name
- MOSAIC 3D Laser System
Indications for Use (Describe)
The MOSAIC 3D Laser System is indicated for use in dermatological procedures
requiring the coagulation of soft tissue, as well as for fractional skin
resurfacing procedures.
Type of Use (Select one or both, as applicable)
- Prescription Use (Part 21 CFR 801 Subpart D)
- Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of
1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79
hours per response, including the time to review instructions, search existing
data sources, gather and maintain the data needed and complete and review the
collection of information. Send comments regarding this burden estimate or any
other aspect of this information collection, including suggestions for
reducing this burden, to:
- Department of Health and Human Services
- Food and Drug Administration
- Office of Chief Information Officer
- Paperwork Reduction Act (PRA) Staff
- PRAStaff@fda.hhs.gov
“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”
510(k) SUMMARY for K233550
A summary of 510(k) safety and effectiveness information in accordance with
the requirements of 21 CFR 807.92.
807.92(a)(1) – Submitter Information
Name| Lutronic Corporation
Address| Lutronic Center 219, Sowon-Ro
Deogyang-Gu, Goyang-Si, KR 410220
Phone number| 978-888-1426
Fax number| N/A
Establishment Registration Number| 1222993
Name of contact person|
- Sarah Dunne
- Senior Regulatory Affairs Specialist, Lutronic Aesthetic 19 Fortune Drive
- Billerica, MA, 01821
Date prepared| 02 JANUARY 2024
807.92(a)(2) – Name of device
Trade or proprietary name| MOSAIC 3D
Common or usual name| Surgical Laser
Classification name| Laser Surgical Instrument for use in General and Plastic
Surgery and in Dermatology
Classification panel| General and Plastic Surgery
Regulation| 21 CFR 878.4810
Product Code(s)| ONG (primary), GEX (secondary)
807.92(a)(3) – Legally marketed device(s) to which equivalence is claimed
| Lutronic Corporation K080932 (06/09/2008) Predicate Solta Medical, Inc
K130193 (06/14/2013) Reference
807.92(a)(4) – Device description
| The MOSAIC 3D Laser System is a non-ablative fractional Er:Glass (Erbium
Glass) laser with a wavelength of 1550 nm. It uses Er:Glass to emit a laser
beam that is then emitted onto the treatment area via the handpiece connected
to the optical fiber of the main body of the system. It is comprised of a main
body, a handpiece connected to an optical fiber, a tip, a footswitch, and
goggles for laser protection. The laser beam is emitted onto the area to be
treated through the tips (roller tip, sapphire tip, comb tip, pill tip)
connected to the handpiece.
|
When the beam contacts tissue the laser beam emits many separate microbeams and creates a microscopic treatment zone (MTZ). Thermal coagulation is then induced in the dermis using the principle of fractional photo thermolysis, sparing the normal skin tissue surrounding the MTZ area. When the laser beam is emitted onto skin tissue, the energy of the beam is absorbed by specific tissues or chromophores such as water and is then converted into thermal energy, causing thermal damage to produce a therapeutic effect.
The MOSAIC 3D Laser System is controlled via a LCD touchscreen guided user interface in the front of the device, which is used to easily configure optimal treatment parameters and check parameters set in the device in the current system mode.
---|---
807.92(a)(5) Intended use of the device
Indications for use| The MOSAIC 3D Laser System is indicated for use in
dermatological procedures requiring the coagulation of soft tissue, as well as
for fractional skin resurfacing procedures.
807.92(a)(6) Summary of the technological characteristics of the device
compared to the predicate
| MOSAIC 3D| MOSAIC HP
K080932
| Fraxel Dual 1550
K130193 (reference)
Indications for Use| The MOSAIC 3D
laser system is indicated for use in dermatological procedures requiring the coagulation of soft tissue, as well as for fractional skin resurfacing procedures.
| The MOSAIC laser system is indicated for use in dermatological procedures
requiring the coagulation of soft tissue| The Fraxel 1550 nm laser is
indicated for use in dermatological procedures requiring the coagulation of
soft tissue, as well as for skin resurfacing procedures. It is also
Laser Type| Er:Glass Fiber laser| Er:Glass Fiber laser| Er:Glass Fiber laser
Wavelength| 1550 nm| 1550 nm| 1550 nm
Pulse Energy/MTZ| 4 – 70 mJ| 4 – 70 mJ| 4 – 70 mJ
Laser beam spot size| 100um| 100um| 200um
Density| 25 – 500 Spot/cm²| 50 – 500 Spot/cm²| UNK or 2500 spots per cm2 over
5 passes (per manual)
Pulse repetition Rate| 169.8 – 447.4 Hz| 42.3 – 588 Hz| 0-3kHz
Interval| 0.3s, 0.5s, 1.0s, single, CW| Single| Single
Pattern Shapes| square, rectangle,
circle
| Not applicable| Not applicable
Tip pattern / sizes| Circle: 4, 6, 8, 10, 12mm dia Square: 6×6, 8×8,
10×10, 12×12, 16×16,
18×18, 20x20mm –
Rectangle: 2×12, 2×15, 4×12, 6×12,
8×12, 8×16, 8x20mm
| L10×10, L6×6, L5×10, H10×10 mm| Width of 15mm and 7mm
Use of tip| Disposable / Reusable| Reusable| Disposable
Cooling Mechanism| Air cooling| Air cooling| Air cooling
Aiming Beam| 658nm < 1mW| 658nm < 1mW| unk
Delivery method| Fiber| Fiber| fiber
Type and Degree of protection against shock| Class I, Type B| Class I, Type B|
Class I, Type B
---|---|---|---
807.92(b)(1) NON CLINICAL TESTS SUBMITTED
- IEC 60601-1: 2012, ed 3.1, Medical Electrical Equipment—Part 1: General Requirements for Basic Safety and Essential Performance
- IEC 60601-1-2 Edition 4: 2014, Medical Electrical Equipment—Part 1-2: General Requirements for Basic Safety and Essential Performance—Collateral Standard: Electromagnetic Compatibility— Requirements and Tests
- IEC 60601-2-22: 2012-10 ed 3.1, Medical Electrical Equipment—Part 2-22: Particular Requirements For Basic Safety And Essential Performance Of Surgical, Cosmetic, Therapeutic And Diagnostic Laser Equipment
- IEC 60825-1 Ed. 3.0 (2014) Safety Of Laser Products—Part 1: Equipment Classification and Requirements
- Cytotoxicity per ISO 10993-5:2009
- Skin sensitization per ISO 10993-10:2021
- Skin Irritation per ISO 10993-23:2021
807.92(b)(2) CLINICAL TESTS SUBMITTED
A clinical study was performed to assess the effect of the laser on the
tissue, healing of the tissue and potential side effects. 15 patients were
treated at a range of treatment settings. Biopsies were taken the day of
treatment and multiple days after treatment. Histological evaluation showed
signs of coagulation formation followed by healing within 4 days. All patients
saw mild anticipated side effects of erythema and edema immediately following
treatment which typically resolved by end of day. There were no adverse events
noted in the duration of the study.
807.92(b)(3) Conclusion
Based on the comparison of the technological characteristics, the
specifications for the Mosaic ED are the same or a subset of the Mosaic 3D
specifications. The additional tips allow the users more options in how the
same energy is shaped during delivery. The new indication of fractional skin
resurfacing procedures is supported by clinical testing. Also, the indication
is similar to the reference device, Fraxel Dual 1550.
References
- HHS Accessibility & Section 508 | HHS.gov
- U.S. Food and Drug Administration
- U.S. Food and Drug Administration
- 510(k) Premarket Notification
- Postmarketing Safety Reporting for Combination Products | FDA
- Device Advice: Comprehensive Regulatory Assistance | FDA
- Contact Us – Division of Industry and Consumer Education (DICE) | FDA
- Medical Device Reporting (MDR): How to Report Medical Device Problems | FDA
Read User Manual Online (PDF format)
Read User Manual Online (PDF format) >>